TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06451770: A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia

Sponsor: Verve Therapeutics, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 132 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,815,344

Rescue Site Savings

+$2,528,512

Unlock Full NCT06451770 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06451770 Rescue Dossier →